Find this week’s updates on 340B litigation to help you stay in the know on how 340B cases are developing across the country. Each week we comb through the dockets of more than 50 340B cases to ...

The 340B drug discount program incentivizes hospitals to purchase outpatient clinics and prescribe more and higher-cost drugs — behaviors that tend to increase costs for the federal government and ...

When the 340B drug pricing program was established in 1992, Congress intended for the program to help low-income and uninsured patients with their prescription drugs. The pharmaceutical companies ...

The Trump administration is pushing significant changes to the healthcare status quo that it says will save money, improve oversight and make the $4.9 trillion sector more efficient. Many of the HHS’ ...

The 340B Drug Pricing Program was created in 1992 and allows hospitals and clinics that treat a large population of low-income and uninsured patients to buy outpatient prescription drugs at a discount ...

HRSA is piloting a back-end rebate model despite CEs and numerous trade associations having raised significant legal, administrative and financial concerns with shifting a discount program to a rebate ...

The 340B Drug Pricing Program was designed to help safety net providers serve low-income patients, but it has since ballooned into a multibillion-dollar system dominated by large health systems — with ...

A federal court this week denied a request from the U.S. Department of Health and Human Services to nix a lawsuit from drugmaker AstraZeneca over the 340B drug discount program. The court said HHS' ...

Here we go again: An op-ed column printed in this publication is yet another example of a drug company-focused view on the 340B Drug Pricing Program, couched in the language of reform. Its criticisms ...

The results indicate that the program could play a role in discouraging use of biosimilars in the United States. Hospitals participating in the 340B Drug Pricing Program had lower biosimilar uptake, ...

New research has found the 340B program is slowing uptake of biosimilars by incentivizing use of more expensive biologics. The 340B program has driven provider variation in the uptake of biosimilars ...

Despite the rancor, there are many bipartisan opportunities for the divided 118 th Congress. Near the top of the to-do list should be reforming the well-intentioned, but poorly designed, 340B drug ...